Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 0.54 |
| ▸ | TUBB4A known ✓ | P04350 | 3/20 | 0.54 |
| ▸ | TUBB known ✓ | P07437 | 3/20 | 0.54 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 3/20 | 0.54 |
| ▸ | TUBA1B known ✓ | P68363 | 3/20 | 0.54 |
| ▸ | TUBA4A known ✓ | P68366 | 3/20 | 0.54 |
| ▸ | TUBB4B known ✓ | P68371 | 3/20 | 0.54 |
| ▸ | TUBB3 known ✓ | Q13509 | 3/20 | 0.54 |
| ▸ | TUBB2A known ✓ | Q13885 | 3/20 | 0.54 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 3/20 | 0.54 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 3/20 | 0.54 |
| ▸ | TUBA1A known ✓ | Q71U36 | 3/20 | 0.54 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 3/20 | 0.54 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 3/20 | 0.54 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 3/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6893117 | 0.88 | HDAC6 (0.62) | PAX8TUBB1LMNACYP2C9KMT2A | |
| SCHEMBL6283178 | 0.87 | PAX8 (0.52) | PAX8TUBB1LMNACYP2C9KMT2A | |
| SCHEMBL6691750 | 0.85 | PAX8 (0.51) | PAX8TUBB1LMNACYP2C9KMT2A | |
| SCHEMBL6278945 | 0.83 | PAX8 (0.55) | PAX8TUBB1LMNACYP2C9KMT2A | |
| SCHEMBL6287108 | 0.83 | PAX8 (0.54) | PAX8TUBB1LMNACYP2C9KMT2A | |
| SCHEMBL6282141 | 0.82 | PAX8 (0.54) | PAX8TUBB1LMNACYP2C9KMT2A | |
| SCHEMBL6286263 | 0.81 | PAX8 (0.55) | PAX8TUBB1LMNACYP2C9KMT2A | |
| SCHEMBL17288342 | 0.81 | PAX8 (0.81) | PAX8TUBB1LMNACYP2C9KMT2A | |
| SCHEMBL6286224 | 0.81 | PAX8 (0.68) | PAX8TUBB1LMNACYP2C9KMT2A | |
| SCHEMBL6699743 | 0.81 | PAX8 (0.52) | PAX8TUBB1LMNACYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846925-B2 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | claimed |
| US-20040142909-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED | 2004-07-22 | — | — | US | claimed |
| US-6720323-B2 | N-((5S)-3,9,10,11-TETRAMETHOXY-6,7-DIHYDRO-5H-DIBENZO(A,C) CYCLOHEPTEN-5-YL)-2-(2-AMINOACETYLAMINO)ACETAMIDE; DESTROYS NEWLY FORMED VASCULATURE WHILE LEAVING UNAFFECTED NORMAL, MATURE VASCULATURE. | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2004-04-13 | — | — | US | claimed |
| US-20030195173-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2003-10-16 | — | — | US | claimed |
| US-6846925-B2 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
| US-20040142909-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED | 2004-07-22 | — | — | US | disclosed |
| US-6720323-B2 | N-((5S)-3,9,10,11-TETRAMETHOXY-6,7-DIHYDRO-5H-DIBENZO(A,C) CYCLOHEPTEN-5-YL)-2-(2-AMINOACETYLAMINO)ACETAMIDE; DESTROYS NEWLY FORMED VASCULATURE WHILE LEAVING UNAFFECTED NORMAL, MATURE VASCULATURE. | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2004-04-13 | — | — | US | disclosed |
| US-20030195173-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195173-A1 | Colchinol derivatives as angiogenesis inhibitors | FLT1, CCNO, FLT4 | TUBB1 159/4885TUBB4A 734/4885TUBB 327/4885 |
| US-20040142909-A1 | Colchinol derivatives as angiogenesis inhibitors | FLT1, CCNO, FLT4 | TUBB1 161/4885TUBB4A 748/4885TUBB 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.